Reference

1. Early Breast Cancer Trialists Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med 1995; 333: 1444.
2. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822.
3. Bonadonna G, Valagussa P. Combined modality approach for high-risk breast cancer. The Milan Cancer Institute experience. Surg Clin North Am 1995; 4: 701-14.
4. Early Breast Cancer Trialist Cooaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy.Lancet 1992; 339: 1-15, 71-85.
5. Koscielny S et al. The natural history of human breast cancer. The relationship between involvement of axillary lymph nodes and the initiation of distant metastases. Br J Cancer 1989; 59: 775.
6. Yeh I et al. Pathological assessment and pathological prognostic factors in operable breast cancer. In: Fowble B et al. (eds) Breast cancer treatment. Mosby Year Book, St. Louis 1991.
7. Nemoto T et al. Management and survival of female breast cancer. Results of a national survey by the American College of Surgeous. Cancer 45: 2917-2924, 1980.
8. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90: 1601-1608, 1998.
9. Eschborn VB. Oncology in practice: Systemic treatment of breast cancer. Springer-Verlag, Heidelberg, 1996: 18.
10. Davidson N, O’Neill A, Vukov A, et al: Effect of chemohormonal therapy in premenopausal node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101). Proc Am Soc Clin Oncol 18: 67a, 1999 (abstr 249)
11. Tormey DC, Gray R, Abeloff MD, et al: Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol 10: 1848-1856, 1992.
12. Albain K, Green S, Osborne K, et al: Tamoxifen (T) versus cyclophosphamide, adriamycin, and 5-FU plus either concurrent or sequential T in postmenopausal receptor (+), node (+) breast cancer: A Southwest Oncology Group phase II Intergroup trial (SWOG-8814, INT-0100). Proc Am Soc Clin Oncol 16: 128a, 1997 (abstr 450)
13. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8: 1005-1018, 1990.
14. International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15: 1385-1394, 1997.
15. Goldhirsch A, Coates AS, Colleoni M, et al: Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference—International Breast Cancer Study Group. J clin Oncol 16: 1358-1362, 1998.
16. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89: 1673-1682, 1997.
17. Harris JR, Lippman ME, Morrow M, Hellman S. Disease of the Breast. Philadelphia, Lippincott-Raven 1996: 562.
18. Henderson IC. Adjuvant systemic therapy of early breast cancer. In: Harris JR, Hellman SA, et al eds. Breast diseases, ed 2. Philadelphia, JB Lippincott, 1991: 427.
19. Goldhirsch A, Gelber RD, Castiglione M, The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1990; 1: 183-188.
20. Goldhirsch A, Gelber RD, Endocrine therapies of breast cancer. Semin Oncol 1996; in press.
21. Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. New York: Lippincott-Raven, 1997: 1594.